{"id":"W2263474571","doi":"10.1016/j.jval.2015.03.1051","title":"Cost-effectiveness of Secukinumab compared to current treatments for the treatment of moderate to severe plaque Psoriasis in Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Secukinumab; Ustekinumab; Medicine; Etanercept; Adalimumab; Infliximab; Ixekizumab; Psoriasis; Quality-adjusted life year; Cost effectiveness; Dermatology; Internal medicine; Psoriatic arthritis; Disease; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000485176,0.0002037721,0.0006222573,0.0001436243,0.00004871802,0.000002928019,0.0001362183,0.0000568791,0.000005655185],"category_scores_gemma":[0.00003836619,0.0001442506,0.0000649491,0.0002640671,0.00001756412,0.00002578225,0.00002037312,0.00004827423,0.000005416891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002256804,"about_ca_system_score_gemma":0.002059717,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8246633,"about_ca_topic_score_gemma":0.5918488,"domain_scores_codex":[0.9980635,0.0007754954,0.0004587418,0.0002775231,0.00006008315,0.0003646771],"domain_scores_gemma":[0.9985718,0.0008674708,0.000135911,0.0002732188,0.00007599594,0.0000755922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.03075048,0.005740536,0.1721975,0.0006510691,0.001553343,0.00001983367,0.03210027,0.4318658,0.001411227,0.001159359,0.001534022,0.3210166],"study_design_scores_gemma":[0.1253422,0.01808875,0.6423878,0.002948046,0.0006876939,0.00006467909,0.008389001,0.004067683,0.1473081,0.001394668,0.04766734,0.001654044],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894481,0.004615832,0.0001759023,0.0003484735,0.000941218,0.003679952,0.0007630413,0.000006944507,0.00002049522],"genre_scores_gemma":[0.998149,0.0004425527,0.0001489449,0.00004814833,0.00001175614,0.001030635,0.0001225515,0.00001437274,0.00003199387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4701903,"threshold_uncertainty_score":0.5901464,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1295162757465326,"score_gpt":0.3380785299799811,"score_spread":0.2085622542334485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}